
Long-term EoE control is multidimensional and extends beyond an eosinophil count or the absence of dysphagia. Durable success includes objective disease control, quality of life, and restoration of normal eating behaviors.

Long-term EoE control is multidimensional and extends beyond an eosinophil count or the absence of dysphagia. Durable success includes objective disease control, quality of life, and restoration of normal eating behaviors.

EoE treatment is not a short-term intervention but an ongoing management process. Setting expectations early can help patients understand why maintenance therapy, reassessment, and treatment adjustments remain necessary.

The most effective EoE therapy is one that controls disease and fits the patient's life. Age, caregiver involvement, treatment feasibility, efficacy, and safety all shape individualized treatment decisions.

Long-term EoE control depends on both sustained response and a treatment patients can realistically maintain. Extended BOS data provide insight into histologic remission, endoscopic improvement, and tolerability over several years.

REMODEL adds esophageal function to the conversation about EoE disease control. Distensibility and esophageal caliber may reveal clinically meaningful changes that symptoms, histology, and visual endoscopy alone cannot fully capture.

Successful EoE treatment requires more than symptom relief. Symptoms, endoscopic improvement, and histologic control provide complementary measures of response while therapeutic mechanisms target inflammation in different ways.

Effective EoE treatment begins with matching therapy to disease characteristics, patient preferences, and the realities of long-term use. Objective reassessment helps determine when it is time to pivot or escalate.

EoE can affect patients across demographic groups, and diagnostic delay may carry structural consequences. Earlier recognition and inflammatory control may help reduce progression toward fibrostenotic disease.

Early EoE recognition depends on looking beyond overt dysphagia and performing an adequate diagnostic evaluation. Careful endoscopy and appropriately distributed biopsies can prevent missed opportunities for diagnosis.

EoE extends beyond eosinophilic inflammation, with epithelial barrier dysfunction helping perpetuate disease activity. Recognizing how patients adapt to chronic symptoms may be equally important for identifying disease earlier.

As the EoE treatment landscape expands, new therapeutic targets may create opportunities for more individualized care. The panel closes the series by connecting emerging science with practical principles for improving long-term EoE management.

Access can determine whether an effective EoE treatment plan becomes a reality. The expert faculty discuss practical strategies for navigating coverage, cost, and authorization barriers to support timely care.

Adherence starts with finding a treatment patients can realistically sustain. The expert faculty discuss how shared decision-making and patient education can help translate an EoE treatment plan into long-term action.

Effective EoE management requires more than controlling disease activity. The panel explores how evolving clinical needs and quality-of-life considerations can guide treatment decisions over time.

EoE monitoring does not end when remission is achieved. The panel explores how individualized surveillance and ongoing patient engagement can help clinicians recognize changes in disease control over time.

Feeling better does not always mean EoE is fully controlled. The panel explores how patient goals, symptoms, endoscopic findings, and histology come together to provide a more complete picture of treatment success.

Biologic evidence in EoE is expanding beyond traditional measures of response. The panel explores how data on esophageal distensibility and pediatric outcomes may refine patient selection and inform clinical decision-making.

Long-term EoE management requires evidence that extends beyond initial treatment response. The panel examines 4-year BOS data and what they reveal about durability of response, tolerability, and sustained disease control.

Effective EoE care requires a treatment plan that works for both the disease and the patient. The expert faculty explore how individualized treatment selection and appropriately timed reassessment can support sustained disease control.

Achieving remission is only one phase of EoE care. The panel explores how induction and maintenance therapies can work together to control inflammation and sustain disease control over time.

Diagnostic delays in EoE can have consequences beyond persistent symptoms. The panel explores how earlier recognition and collaborative care may help address progressive esophageal remodeling and reduce long-term disease burden.

Early EoE diagnosis is about more than relieving symptoms today. The panel explores how timely recognition and treatment of inflammation may help limit progressive structural changes and protect long-term esophageal health.

Accurate EoE diagnosis requires more than recognizing symptoms. The expert faculty highlight how clinical suspicion, appropriate biopsy sampling, histology, and endoscopic findings come together to establish a confident diagnosis.

EoE does not always present as straightforward dysphagia. The panel explores how adaptive eating behaviors, age-specific presentations, atopic comorbidities, and food impaction can provide critical clues for earlier recognition and diagnosis.

In the final episode, each panelist synthesizes their top recommendations for advancing EPI care.

This episode spotlights a recent publication by Ashkar and colleagues—co-authored by Jennifer Geremia—surveying prescribing practices for EPI across a broad cross-section of healthcare professionals.

Clinicians reveal where pancreatic care falls apart—diagnosis delays, post-discharge gaps, lost oncology follow-up—and how to fix handoffs fast.

Why EPI outcomes improve when GI, primary care, nutrition and pain teams coordinate—streamlining labs, vitamins and follow-ups for patients.

Learn how clinicians tailor pancreatic enzyme therapy: insurance, dosing, PPIs, and fixes for nonresponse—plus limits of OTC enzymes.

Learn what happens after suspected EPI: patient education, enzyme therapy tips, nutrition and vitamin checks, plus smoking and alcohol support.

September 7th 2026

October 27th 2026

October 21st 2026

October 5th 2026

September 14th 2026

September 21st 2026